Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Neoadjuvant Therapy in MIBC
NCT03674424Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of avelumab in muscle-invasive bladder cancer (MIBC), sponsored by Institut Jules Bordet. Started Jun 2018; status: completed.
02
Drugs
avelumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03674424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674424.